New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
07:28 EDTBCRXBioCryst price target raised to $24 from $21 at H.C. Wainwright
H.C. Wainwright raised its price target for BioCryst shares to $24 saying two overhangs have been removed with the positive Phase 2a data for oral kallikrein inhibitor 4161 and the recent equity financing. The firm reiterates a Buy rating on the stock.
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
10:51 EDTBCRXBioCryst, ASPR/BARDA amend agreement for development of BCX4430
BioCryst Pharmaceuticals said in a regulatory filing that on August 28, the company and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response amended the Agreement dated March 27 for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. Pursuant to this amendment, ASPR/BARDA exercised an option under the Agreement to authorize $4.2M of funding to enable non-clinical NDA-enabling toxicology studies and obligated an additional $1.2M of new funding to support previously authorized drug substance and drug product cGMP manufacturing by U.S. suppliers for non-clinical and clinical activities. The execution of the Amendment represents an additional $5.4M in funding BioCryst to support BCX4430 drug manufacturing and toxicology studies, and increases the total potential value of the contract to $36.2M. The period of performance under the exercised options extends through April 14, 2017, while the period of performance under the base period of the contract remains unchanged, extending through September 30, 2016.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use